The Comparative Effectiveness of Enlonstobart and Camrelizumab as Second-Line Recurrent or Metastatic Cervical Cancer Therapies: Matching-Adjusted and Simulated Treatment Comparisons.

PFS showed a favorable trend but was not statistically significant (HR=0.69, 95% CI 0.42–1.14, p=0.15).

also in 993 other papers

After matching-based weighted adjustment, the enlonstobart group had a median PFS extension of 3.43 months compared to the camrelizumab group (HR=0.69; 95% CI 0.42–1.14; p=0.15), but the difference did not reach statistical significance ( Figure 2 and Table 2 ).

also in 75,281 other papers

These findings were consistent with the primary MAIC analysis, with both methods demonstrating enlonstobart’s superiority over camrelizumab for OS, while for PFS, both approaches consistently favored enlonstobart, though the STC analysis achieved statistical significance where the MAIC analysis showed a trend in the same favorable direction but without statistical significance.

also in 33,237 other papers